Liraglutide modulates adipokine expression during adipogenesis, ameliorating obesity, and polycystic ovary syndrome in mice
- 98 Downloads
The incidence of obesity is increasing among all age groups throughout the world and it is highly associated with numerous other metabolic disorders, such as insulin resistance, polycystic ovarian syndrome (PCOS) etc.
Methods and Results
Using in vitro and in vivo approach, this study investigated the adipokine profile after liraglutide on differentiated murine 3T3-L1 pre-adipocytes. Effect of liraglutide on DHEA-induced PCOS mice were investigated. This study showed Liraglutide treatment resulted in up-regulation of adiponectin and IL-6 along with down-regulation of ICAM 1 in differentiated 3T3-L1 cells. Liraglutide in absence of other differentiating factors, significantly increased glucose, lipid uptake and PPARγ, C/EBPα expression in the adipocytes suggesting its ability to solely promote pre-adipocyte differentiation into mature adipocyte. Liraglutide treatment showed increased adiponectin expression and decreased number of cystic follicles, body weight, circulating glucose, triglyceride and testosterone levels in comparison to the PCOS induced mice.
This study suggests that adiponectin may act as a link between metabolic disorders and PCOS and that liraglutide might be a promising therapeutic agent for the treatment of PCOS in addition to obesity and insulin resistance.
The study shows the impact of GLP-1 analogue, liraglutide’s impact on adipokine secretion in 3T3L1 adipocytes.
For the first time, showing that liraglutide in the absence of other differentiating factors (IBMX, insulin, and dexamethasone), significantly increased glucose, lipid uptake and PPARγ, C/EBPα expression in the adipocytes suggesting its ability to solely promote pre-adipocyte differentiation into mature adipocyte.
Also, for the first time it shows that liraglutide through the up-regulation of adiponectin manages PCOS in mice.
KeywordsLiraglutide Adipocyte Adiponectin PCOS
BITS RIG financial assistance is acknowledged. A.S. acknowledges University Grant Commission, India for providing research fellowship. J.R.D.F. acknowledges SERB for financial assistance.
A.S. did the animal-related work and wrote the manuscript. J.R.D.F. did the cell differentiation, partial IHC, and wrote, edited the manuscript. G.C. did the adipokine array work and edited the manuscript. A.K. edited the manuscript. A.B. planned the work and edited the manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All animal experimentation and procedures were approved by the Institutional Animal Ethics committee of Birla Institute of Technology and Science (BITS) Pilani Rajasthan, Reference number IAEC/REC/19/21.
- 1.D.S. Gedam, Childhood obesity—challenges in the Indian scenario. Int. J. Med. Res. Rev. 1(1), 1–4 (2013).Google Scholar
- 9.Y. Li, D. Tweedie, M.P. Mattson, H.W. Holloway, N.H. Greig, Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. J. Neurochem. 113(6), 1621–1631 (2010)Google Scholar
- 11.M.E.J. Lean, D. Malkova, Altered gut and adipose tissue hormones in overweight and obese individuals: cause or consequence?. Int. J. Obes. 3(1), 35–42 (2015)Google Scholar
- 13.S.X. Wang, Y. Xie, X. Zhou, W.W. Sha, W.L. Wang, L.P. Han et al. Effect of glucagon-like peptide-1 on hypoxia-reoxygenation induced injury in neonatal rat cardiomyocytes. Zhonghua Xin Xue Guan Bing Za Zhi 38, 72–75 (2010)Google Scholar
- 18.L. Li, Z. Miao, R. Liu, M. Yang, H. Liu, G. Yang, Liraglutide prevents hypoadiponectinemia-induced insulin resistance and alterations of gene expression involved in glucose and lipid metabolism. Mol. Med. 17(11–12), 1168 (2011)Google Scholar
- 20.G. Díaz-Soto, D.A. de Luis, R. Conde-Vicente, O. Izaola-Jauregui, C. Ramos, E. Romero, Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study. Diabetes Res. Clin. Pract. 104(1), 92–96 (2014)CrossRefGoogle Scholar
- 24.X. Li, L. Jiang, M. Yang, Y.W. Wu, S.X. Sun, J.Z. Sun, CTRP3 modulates the expression and secretion of adipokines in 3T3-L1 adipocytes. Endocr. J. pp. EJ14–0161 (2014)Google Scholar
- 33.A.H. Balen, L.C. Morley, M. Misso, S. Franks, R.S. Legro, C.N. Wijeyaratne, E. Stener-Victorin et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum. Reprod. Update 22, 687–708 (2016)Google Scholar
- 35.M.J. Sever, T. Kocjan, M. Pfeifer, N.A. Kravos, A. Janez, Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur. J. Endocrinol. 170, 451–459 (2014)CrossRefGoogle Scholar
- 46.T. Vilsboll, M. Zdravkovic, T. Le-thim, T. Krarup, O. Schmitz, J. Courreges et al. Liraglutide significantly improves glycemic control, and lowers body weight without risk of either major or minor hypoglycaemic episodes in subjects with Type 2 diabetes. Diabetes 30(6), 1608–1610 (2006)Google Scholar
- 51.D. Wang, A. Haile, L.C. Jones, Rosiglitazone-induced adipogenesis in a bone marrow mesenchymal stem cell line. Biomed. Sci. Instrum. 47, 213–221 (2011)Google Scholar
- 54.R.E. Pasquali, F.R. Casimirri, R.O. De Iasio, P.A. Mesini, S.T. Boschi, R.O. Chierici, R.I. Flamia, M.I. Biscotti, V.A. Vicennati, Insulin regulates testosterone and sex hormone-binding globulin concentrations in adult normal weight and obese men. J. Clin. Endocrinol. Metab. 80(2), 654–658 (1995)Google Scholar
- 66.A. Iwase, M. Goto, T. Harata, S. Takigawa, T. Nakahara, K. Suzuki et al. Insulin attenuates the insulin-like growth factor-I (IGFI)-Akt pathway, not IGF-I-extracellularly regulated kinase pathway, in luteinized granulosa cells with an increase in PTEN. J. Clin. Endocrinol. Metab. 94, 2184–2191 (2009)CrossRefGoogle Scholar
- 68.F. Qu, F.F. Wang, X.E. Lu, M.Y. Dong, J.Z. Sheng, P.P. Lv et al. Altered aquaporin expression in women with polycystic ovary syndrome: hyperandrogenism in follicular fluid inhibits aquaporin-9 in granulosa cells through the phosphatidylinositol 3-kinase pathway. Hum. Reprod. 25(6), 1441–1450 (2010)CrossRefGoogle Scholar
- 71.F. Comim, S. Stubbs, K. Hardy, S. Franks, Localisation of adiponectin receptors in normal and polycystic ovaries. Endocr. Abstr. 21, 317 (2010)Google Scholar